FDA lifts partial hold on Salarius' Ewing sarcoma drug trial
Houston biotech Salarius Pharmaceuticals has received some positive news from the FDA.
Salarius announced Tuesday that the agency removed a partial clinical hold from its Phase I/II trial for its LSD1 inhibitor seclidemstat to treat the bone cancer Ewing sarcoma. Last year, Salarius decided to pause new enrollments when an individual died after taking the treatment, and Salarius reported the details to the FDA. While the cause of death remains unclear, it did qualify as a suspected unexpected serious adverse reaction (SUSAR).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.